[Osteoporosis treatment evaluation with desoxypiridinoline urine detection in postmenopause patients].
OBJECTIVE
to evaluate urinary desoxypiridinoline (Dpd) levels in postmenopause patients, with osteoporosis or osteopenia after treatment with sodium alendronate.


METHODS
a quasiexperimental study was carried out in 118 patients, aged from 41 to 69 years. According to the densitometry results and treatment received, we formed five groups: group I, patients with osteoporosis, treated with 10 mg/day of alendronate; group IIA, patients with osteopenia treated with alendronate 5 mg/day; group IIB, patients with osteopenia treated with hormonal therapy replacement (HTR); group IIIA, patients with normal densitometry treated with change of life style habits; and group IIIB, patients with normal densitometry treated with HTR. Dpd urinary levels were measured in all patients at the beginning and 60 days after. The statistical analysis was t Student paired.


RESULTS
the group I diminished 7.8 nmol Dpd/mmol Cr with a p = 0.001. In the other groups the reduction of the urinary Dpd level was not significant.


CONCLUSIONS
in osteoporosis the urinary Dpd excretion diminishes after 60 days of treatment with 10 mg/day of sodium alendronate.
Solís-Cabrera
Bella Herlinda
BH
Unidad de Medicina Familiar 10, Instituto Mexicano del Seguro Social (IMSS), Jalapa, Veracruz, México. bellita1702@hotmail.com.mx
Del Carmen Ramírez-Benítez
María
M
Cocotle-Ronzón
Yolanda
Y
Moreno-Todd
Magdalena
M
Soto-Cid
Abraham Heriberto
AH
D000328:Adult; D000368:Aged; D019386:Alendronate / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000652:urine*; D017698:Postmenopause
D050071:Bone Density Conservation Agents; D019386:Alendronate